Relationship between ABCF2 expression and response to chemotherapy or prognosis in clear cell adenocarcinoma of the ovary.

Abstract

OBJECTIVES:

The purpose of this study was to evaluate the association of ABCF2 (adenosine triphosphate-binding cassette superfamily F2) protein expression with response to chemotherapy and prognosis in patients with clear cell adenocarcinoma (CCC) of the ovary.

METHODS:

One hundred sixty-five patients with CCC were studied, and cytoplasmic ABCF2 expression was detected by immunohistochemical staining. All patients underwent platinum-based primary chemotherapy followed by primary surgery.

RESULTS:

Adenosine triphosphate-binding cassette superfamily F2 expression was detected in 118 (71.5%) of 165 patients and was not related to age or clinical stage. The response rate to chemotherapy in 38 patients with measurable disease was 47.3% (18/38). The response rate tended to be higher in patients without ABCF2 expression than in those with ABCF2 expression; however, this difference was not significant (66.7% vs 34.8%, P = 0.096). There was no significant difference in overall survival between ABCF2-positive and ABCF2-negative cases (median survival time, 1175 vs 1257 days; P = 0.24).

CONCLUSIONS:

Adenosine triphosphate-binding cassette superfamily F2 protein was highly expressed in CCC of the ovary, but expression was not related to age, clinical stage, chemoresponse, or prognosis.

• Authors: Hiroshi Tsuda, Kiyoshi Ito, Nobuo Yaegashi, Akira Hirasawa, Tamotsu Sudo, Tsunekazu Kita, Yoshito Terai, Junzo Kigawa, Toru Sugiyama, Daisuke Aoki
• Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society (Int J Gynecol Cancer) Vol. 20 Issue 5 Pg. 794-7 (Jul 2010) ISSN: 1525-1438 [Electronic] England
• PMID: 20973270 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• ABCF2 protein, human
• ATP-Binding Cassette Transporters
• Antineoplastic Agents
• Platinum Compounds

Topics

• ATP-Binding Cassette Transporters (biosynthesis)
• Adenocarcinoma, Clear Cell (drug therapy, metabolism)
• Adult
• Aged
• Antineoplastic Agents (therapeutic use)
• Female
• Humans
• Immunohistochemistry
• Middle Aged
• Ovarian Neoplasms (drug therapy, metabolism)
• Platinum Compounds (therapeutic use)
• Prognosis
• Retrospective Studies
• Survival Analysis